How the Peritoneal Equilibration Test Characterizes Peritoneal Transport
The peritoneal equilibration test (PET) should be performed approximately 1 month after PD initiation using a 4-hour dwell with 2.5% dextrose, measuring the dialysate-to-plasma (D/P) creatinine ratio and dialysate-to-initial dialysate (D/D₀) glucose ratio to classify patients as low, low-average, high-average, or high transporters—this classification directly guides prescription adjustments and predicts ultrafiltration capacity. 1
Understanding PET Characterization
The PET categorizes peritoneal membrane transport characteristics through specific measurements:
- D/P creatinine at 4 hours: Reflects small solute transport rate across the peritoneal membrane
- D/D₀ glucose: Indicates glucose absorption rate and correlates inversely with ultrafiltration capacity
- Net ultrafiltration volume: Directly measures fluid removal capacity
High transporters rapidly equilibrate solutes (high D/P creatinine) and absorb glucose quickly (low D/D₀), resulting in poor ultrafiltration—they require short dwell times with automated PD or frequent exchanges. Low transporters have slower solute equilibration but maintain ultrafiltration well, though they may struggle to achieve adequate small solute clearance if body size is large. 1
Timing and Clinical Application
Perform the baseline PET at 1 month post-initiation 1—earlier testing (within the first week) is unreliable because transport characteristics change significantly during the first month, with D/P creatinine increasing substantially between week 1 and week 4. 2 Testing during peritonitis or within 1 month after resolution yields falsely elevated transport rates and should be avoided. 3
The baseline PET serves to identify patients who will develop problems:
- High transporters will eventually face ultrafiltration failure when residual kidney function declines
- Low transporters in large patients may have inadequate peritoneal clearance
- Average transporters have the most prescription flexibility 1
Detecting Progressive Membrane Dysfunction
Clinical Surveillance Strategy
Monitor drain volumes and clinical volume status at every clinic visit rather than performing routine serial PETs. 3 The 2006 KDOQI guidelines explicitly state that longitudinal laboratory monitoring of peritoneal transport is not routinely indicated in stable patients. 3
Repeat PET testing only when clinically indicated: 3
- Suspected ultrafiltration failure: Patient requires increasing hypertonic exchanges to maintain euvolemia, develops persistent edema despite adequate prescription, or shows declining drain volumes
- After peritonitis: Reassess 1 month post-resolution if clinical concerns persist
- Failure to thrive: Unexplained clinical deterioration despite apparently adequate prescription
- Loss of residual kidney function: Sudden decrease in urine output may unmask previously compensated membrane dysfunction
Diagnostic Approach to Ultrafiltration Failure
When ultrafiltration insufficiency is suspected, use a 4-hour PET with 4.25% dextrose (not the standard 2.5%) and add sodium measurements: 4, 5
- Net UF <400 mL at 4 hours with 4.25% dextrose indicates UF failure
- Measure the sodium dip at 1 hour: A dip ≤5 mmol/L or sodium sieving ratio ≤0.03 confirms intrinsic membrane dysfunction (loss of aquaporin-mediated water transport) 4
- Progressive decrease in sodium dip over time is the most sensitive early marker of developing membrane dysfunction, even before changes in D/P creatinine or ultrafiltration become apparent 5
The sodium dip specifically identifies type I membrane failure (loss of osmotic conductance to glucose) versus type II failure (increased effective peritoneal surface area from high transport alone). 4
Reducing Progressive Membrane Dysfunction
Primary Prevention Strategies
Minimize peritonitis episodes—peritonitis is the major modifiable risk factor for accelerated membrane dysfunction. Each episode causes transient high transport status and may contribute to permanent membrane injury. 3
Preserve residual kidney function aggressively: 3
- Avoid nephrotoxic medications (NSAIDs, aminoglycosides)
- Prevent intravascular volume depletion
- Avoid overzealous blood pressure control that compromises renal perfusion
- Monitor 24-hour urine volume at every clinic visit
Consider biocompatible PD solutions when available—newer solutions with lower glucose degradation products and neutral pH may reduce membrane injury, though long-term outcome data remain limited. 3
Management of Detected Dysfunction
For high transporters with declining ultrafiltration: 1, 4
- Switch to automated PD with short dwell times (1-2 hours)
- Use icodextrin for the long daytime dwell (CAPD) or nighttime dwell (APD)
- Increase glucose concentrations only as needed for volume control
- Consider modality transfer to hemodialysis if lifestyle becomes unmanageable or if encapsulating peritoneal sclerosis risk is concerning with prolonged PD duration
For progressive membrane dysfunction with low osmotic conductance: 4
- This typically necessitates hypertonic glucose exchanges
- In the absence of residual kidney function, transfer to hemodialysis is often required
- Discuss encapsulating peritoneal sclerosis risk, particularly if PD duration exceeds 5-8 years
Critical Pitfall
Do not perform routine annual PETs in stable patients—this represents a departure from earlier practice and reduces unnecessary testing burden. 3 Instead, focus clinical surveillance on drain volumes, hypertonic solution requirements, and volume status. Reserve formal PET testing for when clinical assessment suggests a problem requiring objective confirmation and prescription modification.
The most recent evidence indicates that peritoneal transport status has become less prognostically significant in contemporary practice 6, likely because individualized prescriptions based on transport characteristics mitigate the historical mortality risk associated with high transport status. This reinforces that PET results should guide prescription optimization rather than serve as fixed outcome predictors.